A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS): Preliminary Results of Dose Escalation
Year: 2021
Type: article
Authors: Brenda M. Sandmaier, D. Scott Wilbur, Donald K. Hamlin, Phuong Vo, Roger Wong, Kelsey Baker, Robyn Haaf, Michelle E. Bouvier, Manuela C. Matesan, Yawen Li, Johnnie J. Orozco, Margaret Nartea, Erlinda B. Santos, Eric Dorman, Hubert Vesselle, David H. Lewis, Sanaz Behnia, Damian J. Green, Robert C. Emery, Joseph G. Rajendran, Ted A. Gooley, Rainer Storb
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W3126719292